16 Exenatide 5 mcg twice daily (mean standard deviation
1998 reported low-nanomolar GHS-R1a binding affinity and growth hormone release at potency comparable to GHRP-6 in rat pituitary cells, anesthetized rats, and conscious swine, with no detectable elevation of plasma ACTH, cortisol, prolactin, FSH, LH, or TSH at doses greater than 200-fold above the GH ED50 [3]
The theory is that the bodys signaling pathways reach their limit at low concentrations regardless of body size
Radioligand binding uses a radioactively labelled ligand to measure how a test molecule competes for the binding site
Advise them to seek medical advice if such symptoms occur [see WARNINGS AND PRECAUTIONS ]
Injections spaced 3.5 5 days apart for stable blood levels